Research programme: neurokinin-1 receptor antagonists - OPKO Health

Drug Profile

Research programme: neurokinin-1 receptor antagonists - OPKO Health

Alternative Names: NK-1 antagonists - Schering-Plough; OPK 88002

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer OPKO Health
  • Class Antiemetics; Antipruritics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pruritus
  • No development reported Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 09 May 2017 OPKO Health plans a phase IIa trial for Pruritus
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in USA (PO)
  • 12 Nov 2009 OPKO Health acquires the neurokinin-1 antagonist programme from Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top